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NHLBI Clinical Proteomics Programs
This Request for Application (RFA) will establish
Clinical Proteomics Programs to promote systematic,
comprehensive, large-scale validation of existing and
new candidate protein markers that are appropriate
for routine use in the diagnosis and management of
heart, lung, blood, and sleep diseases. These programs
will facilitate validation of protein panels that may be
used to predict disease susceptibility or to assist in dif-
ferential diagnosis, disease staging, selection of indi-
vidualized therapies, or monitoring of treatment
responses. In addition, this RFA seeks to establish a
high quality education and skills development pro-
gram to encourage and ensure that scientists develop
competencies and expertise needed to address the
complex, multifaceted challenges in clinical pro-
teomics.
Heart, lung, blood, and sleep diseases are major
causes of morbidity and mortality. Cardiovascular dis-
ease is the number one killer in the United States in
both men and women, across all major racial groups
and totals nearly one million deaths a year. Lung dis-
eases such as chronic bronchitis, emphysema, asthma
and other obstructive or interstitial conditions
account for more than 230,000 deaths annually, plac-
ing an enormous burden on our healthcare system.
Blood diseases such as venous thrombosis and pul-
monary embolisms are causes of significant public
health concern, as well. Sleep disorders and insuffi-
cient sleep represent severe health concerns for tens of
millions of Americans.
Improving patient care through the use of pro-
tein markers is well established clinically. For example,
the deﬁnition of heart attack, as well as the determina-
tion of the beneﬁt derived from antithrombotic treat-
ments, rests on serum troponin measurement. The
detection of extremely small quantities of this protein
identiﬁes patients at high risk for adverse outcomes as
well those that will derive greater benefit from
antithrombotic and other interventional strategies.
Assay of the B-type natriuretic peptide also con-
tributes to standard clinical information in the diag-
nosis of congestive heart failure. Myeloperoxidase was
recently shown to help in the diagnosis of atheroscle-
rosis and acute coronary syndromes.
The predictive values, sensitivity, and speciﬁcity
of many of the individual protein markers, currently
in clinical use, could potentially be enhanced if ana-
lyzed and measured in a panel. Observational studies
have shown that combining protein markers troponin
I, C-reactive protein and B-type natriuretic peptide
into panels can provide valuable information on strati-
fying risk for acute coronary syndromes. Panels of
protein markers, appropriately validated, could facili-
tate better and earlier diagnosis, improve disease stag-
ing and selection of individual therapies and lead to
more reliable monitoring of treatment responses, lead-
ing to substantial improvements in public health.
The application of proteomics in the clinical
environment is limited due to a lack of knowledge
regarding which proteins are most useful for analysis
and how data are interpreted and represented.
Important research needs include the identiﬁcation of
panels of protein markers that are likely to provide
useful clinical information, design of practical assays
for these panels, and validation of these panels and
assays in well characterized populations of human
subjects. The emergence of clinical proteomics
promises major advances in disease management, pro-
vided that a continuous channel exists for translating
protein discoveries into tangible clinical beneﬁts.
The purpose of this RFA is to establish an infra-
structure for research teams to validate protein panels
and to measure multiple candidate markers accurately,
for heart, lung, blood, and sleep diseases. The Clinical
Proteomics Programs established for this purpose will
design panels of candidate proteins for disease areas,
develop high throughput analytic methods, assess the
predictive value of these proteomic measurements
using biological specimens and clinical data from
existing study populations, and establish procedures
and standards for quality control.
A major shortfall of clinical proteomics is the lack
of a robust infrastructure for clinical candidate panel
validation. Validation is necessary to conﬁrm the rela-
tionship to the target disease in large numbers of
patient samples and requires highly standardized pro-
tein measurement systems. The samples must be
derived from well characterized sample sets with associ-
ated high-quality clinical information. The validation
process provides the critical evidence necessary for
translating protein knowledge into practices impacting
public health. A signiﬁcant opportunity now exists to
enhance the validation stage and help translate protein
discoveries into clinical practice. Many completed and
ongoing clinical trials and epidemiologic studies have
disease associated biological samples in addition to
detailed clinical data. Leveraging this investment will
enhance validation efforts.
Panels of protein markers in the following areas
would represent appropriate topics for proposed pro-
jects. This list is not intended to be all-inclusive, and
other topics should be considered. 1) Predict suscepti-
bility to coronary artery disease or acute and chronic
pulmonary disease; 2) Assess the severity and rate of
progression of atherosclerosis or pulmonary disease; 3)
Differential diagnosis for patients presenting with
shortness of breath, chest pain or elevated blood pres-
sure; 4) Detect occult myocardial infarction and sub-
clinical cardiac disease and/or damage; 5) Select
optimal, individualized medical management strate-
gies; 6) Monitor therapeutic and adverse responses to
antihypertensive drugs or drugs for asthma and other
lung diseases such as inhaled corticosteroids, bron-
chodilators, and leukotrienes; 7) Identify early stages
of pulmonary disease before signiﬁcant pathogenesis
has occurred; 8) Evaluate risk of thrombosis in indi-
viduals with a predisposition to cardiovascular disease
or stroke; 9) Evaluate risk of bleeding and appropriate
management strategies in patients with bleeding disor-
ders - hemophilia, autoimmune blood disorders, von
Willebrand disease; 10) Manage anticoagulation ther-
apy in patients with thromboembolic disorders; 11)
Identify markers for early diagnosis and prognosis of
heart, lung, blood, and sleep disorders; 12) Develop
tests to rapidly and accurately distinguish throm-
boembolic stroke from hemorrhagic stroke.
Projects outside the scope of this RFA will not be
considered responsive and include: 1) Studies that do
not address heart, lung, blood, or sleep disorders;
2) Studies that are focused on developing new pro-
teomic technologies to identify protein markers
3) Proteomic discovery efforts.
We encourage inquiries concerning this RFA and
welcome the opportunity to answer questions from
potential applicants. It is highly recommended that
prospective applicants contact program staff (please see
the “Contact” section below) about proposed projects. 
A Clinical Proteomics Program should be an
identifiable organizational unit formed by a single
institution or a consortium of cooperating institu-
tions. Each Clinical Proteomics Program must pro-
vide a multidisciplinary team structure, ensuring
effective coordination and integration between the
selection and validation components of the Program.
The team should encompass multi-disciplinary exper-
tise and should include proteomic researchers, bio-
engineers, clinical chemists, protein chemists, experts
in biostatistics and bioinformatics, clinical investiga-
tors, and epidemiologists. 
The marker selection process should focus on the
design of protein marker panels that are most useful in
clinical situations with under met needs. The team
should primarily be responsible for prioritizing candi-
date protein markers and panels for validation. The
selection component should actively develop candidate
protein marker panels from a wide range of sources,
such as proteomic discovery efforts, published reports,
differential expression based research studies and in sil-
ico sequence-based predictions.
The use of biological samples obtained by mini-
mally invasive methods (e.g., blood, sputum, and
urine) is encouraged. Samples from ongoing studies
can also be used provided appropriate Institutional
Review Board (IRB) amendments to existing proto-
cols have been obtained. 
Since quantitative measurements of candidate
markers in large and well deﬁned clinical samples is
central to the validation effort, criteria for the selec-
tion of the source material as well as the criteria for
validation of the candidate markers must be speciﬁed.
Where possible, existing technology platforms should
be explored as multiplexing tools during panel devel-
opment. Efforts to minimize sample consumption are
encouraged to ensure the maximum number of assays.
Emphasis will be placed on development of panels
with high predictive value, speciﬁcity, and sensitivity;
development of ﬂexible assay protocols to accommo-
date the inclusion of newly identified proteins into
ongoing validation efforts; refinement and develop-
ment of innovative biostatistical tools and methods
for selection of protein marker panels and for increas-
ing the diagnostic sensitivity and speciﬁcity; and assay
development applicable to clinical settings.
The multidisciplinary team will also evaluate pre-
analytic issues, (including those relating to sample col-
lection, storage, processing, and handling), and set
criteria, standardize, and implement preanalytic pro-
tocols prior to validation. Each Clinical Proteomics
Program should have access to characterized samples
with well defined clinical data and the appropriate
IRB approvals before funding. Furthermore, they
should operate on an ‘open source’ model system,
making the data, statistical and bioinformatic tools
that are generated and developed in the programs,
accessible to the public domain within a time period
to be determined at the first meeting of the Inter-
Program Steering Committee.
An Inter-Program Steering Committee (with
membership from all the programs) will be appointed
and will have scientific management oversight and
responsibility for developing communication, coordi-
nation and collaboration among the Programs. In
addition, there will be an External Scientific Panel,
advisory to the National Heart, Lung and Blood
Institute (NHLBI) that will evaluate the progress of
the Clinical Proteomics Programs.
In order to facilitate the functions that are com-
mon to each program, one of the programs will be
selected to function as an Administrative Coordinating
Center (ACC) for all the programs. Therefore, appli-
cants must include as a separate section in their pro-
posal, a description of an Administrative Coordinating
Center that will be reviewed separately, independent of
the scientiﬁc application. Speciﬁcation for the ACC
application can be found under the section, “Packaging
the Clinical Proteomics Program Application”.
Each program is expected to develop mechanisms
towards education of skills necessary for clinical pro-
teomics. Full implementation of a nationwide effort in
translational research for clinical proteomics requires
availability of trained M.D., M.D. /Ph.D., and Ph.D.
scientists. These individuals must be knowledgeable
about the diverse aspects of clinical proteomics and able
to integrate the translational and clinical concepts nec-
essary for application to heart, lung, blood, and sleep
diseases. One unique feature of the Clinical Proteomics
Program is to function as a spring board for advancing
education, at the National level, by establishing various
mechanisms, such as specialized short courses, and
‘hands on’ programs that will focus on guiding gradu-
ate students, trainees, technical personnel, M.D./Ph.D.
and Ph.D. scientists in translation research for clinical
proteomics. Both Clinical Proteomics Program and
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these educational opportunities.
This RFA will use the National Institutes of Health
(NIH) cooperative agreement (U01) award mechanism.
In the cooperative agreement mechanism, the Principal
Investigator retains the primary responsibility and domi-
nant role for planning, directing, and executing the pro-
posed project, with NIH staff being substantially
involved as a partner with the Principal Investigator, as
described under the section "Cooperative Agreement
Terms and Conditions of Award"
Prospective applicants are asked to submit a letter
of intent that includes the following information:
descriptive title of the proposed research; name,
address, and telephone number of the Principal
Investigator; names of other key personnel; participat-
ing institutions; number and title of this RFA.
Although a letter of intent is not required, is not bind-
ing, and does not enter into the review of a subse-
quent application, the information that it contains
allows NHLBI staff to estimate the potential review
workload and plan the review.
Applications must be prepared using the PHS
398 research grant application instructions and forms
(rev. 5/2001). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System
(DUNS) number as the Universal Identifier when
applying for federal grants or cooperative agreements.
The DUNS number can be obtained by calling 866-
705-5711 or through the web site at http://www.
dunandbradstreet.com/. The DUNS number should
be entered on line 11 of the face page of the PHS 398
form. The PHS 398 is available at http://grants.nih.
gov/grants/funding/phs398/phs398.html in an interac-
tive format. For further assistance contact GrantsInfo,
301- 435-0714, email: GrantsInfo@nih.gov.
Each application to establish a Clinical
Proteomics Program must be submitted as one appli-
cation by a Clinical Proteomics Program Director,
who will be responsible for organizing and maintain-
ing effective integration and interaction of the pro-
gram. A clear description of interaction among the
various components, plans for communication, collab-
oration and sharing among investigators in the Clinical
Proteomics Program should be included. The Clinical
Proteomics Program Director should also indicate the
mechanism for handling day-to-day administrative
details, program, coordination, planning and evalua-
tion. The director will be required to have a minimum
of 25 percent level of effort, and the responsibility of
oversight and coordination of all projects or compo-
nents of the Program, whether or not they are at
his/her institution. Each program should clearly out-
line its administrative and organizational structure.
Applications should include appropriate budget
forms providing adequate budget justiﬁcation with all
applicable direct and facilities and administrative
costs. Estimating of stafﬁng needs, including principal
investigator, other professional and support staff must
be included. During the course of the project period,
it is anticipated that technologies will improve and the
proposed studies may change. Accordingly, it is
expected that the principal investigators will be
allowed adjustments in their scientific projects to
accommodate such things. Budgets should include
travel costs for Awardees Meetings and Inter-Program
Steering Committee Meetings, as detailed under the
section titled, “Special Requirements” along with
statements indicating willingness to participate in
these meetings and abide by its governance.
An educational component is another integral
part of each Clinical Proteomics Program. A clear
description of the efforts to educate and cross train
across disciplines of clinical proteomics must be out-
lined, including the plans for developing short courses
and ‘hands on’ programs. The process of selection and
monitoring of candidates for these educational activi-
ties must be portrayed as well.
A separate section not exceeding 5 pages, detailing
plans for an Administrative Coordination Center,
should be included in each Clinical Proteomics
Program application. This section should be placed fol-
lowing the section on the Research Plan. The Center
will facilitate functions common to all the Clinical
Proteomics Programs, coordinate meetings of the
awardees, the Inter-Program Steering Committee and
the External Advisory Panel, and manage a Clinical
Proteomics Program intranet website. The Center will
also be responsible for setting up the monthly confer-
ence calls of the Steering Committee. This section
should also include separate budget justiﬁcation pages
for the operation of the Administrative Coordination
Center not to exceed 100,000 direct costs in any year.
Applications should provide adequate budget justiﬁca-
tion with all applicable direct and facilities and admin-
istrative costs, including estimated costs associated with
the travel of the External Advisory Panel (6-8 mem-
bers). Estimation of stafﬁng needs and communication
costs must be included. The award will be subject to
administrative review annually.
Applications not conforming to these guidelines
will be considered unresponsive to this RFA and will
be returned without further review.
The RFA label available in the PHS 398 (rev.
5/2001) application form must be afﬁxed to the bot-
tom of the face page of the application. Type the RFA
number on the label. Failure to use this label could
result in delayed processing of the application such
that it may not reach the review committee in time
for review. In addition, the RFA title and number
must be typed on line 2 of the face page of the appli-
cation form and the YES box must be marked. The
RFA label is also available at: http://grants.nih.gov/
grants/funding/phs398/labels.pdf.
The Center for Scientiﬁc Review (CSR) will not
accept any application in response to this RFA that is
essentially the same as one currently pending initial
review, unless the applicant withdraws the pending
application. However, when a previously unfunded
application, originally submitted as an investigator-
initiated application, is to be submitted in response to
an RFA, it is to be prepared as a new application.
That is, the application for the RFA must not include
an Introduction describing the changes and improve-
ments made, and the text must not be marked to indi-
cate the changes from the previous unfunded version
of the application.
Letters of intent are due 17 September 2004.
Applications are due 14 October 2004. The earliest
anticipated start date is July 2005.
Contact: Pothur R Srinivas, Division of Heart
and Vascular Diseases, NHLBI, 6701 Rockledge
Drive, Rm 10188, Bethesda, MD 20892-0001 USA,
301-435-0550, fax: 301-480-2858, email:
ps241q@nih.gov; Anne P. Clark, Chief, Review
Branch, Division of Extramural Affairs, NHLBI,
6701 Rockledge Drive, Rm 7214, MSC 7924,
Bethesda, MD 20892-7924 USA, Bethesda, MD
20817 (for express/courier service), 301-435-0270,
fax: 301-480-0730, e-mail: ac42y@nih.gov.
Reference: RFA No. RFA-HL-04-019
New Technology for Proteomics and Glycomics
(SBIR/STTR)
Notice: this program announcement (PA) must be
read in conjunction with the current Omnibus
Solicitation of the National Institutes of Health
(NIH), Centers for Disease Control and Prevention
(CDC), and Food and Drug Administration (FDA)
for Small Business Innovation Research (SBIR) and
Small Business Technology Transfer (STTR) Grant
Applications. The solicitation (see http://grants.
nih.gov/grants/funding/sbirsttr1/index.pdf or
http://grants.nih.gov/grants/funding/sbirsttr1/index.
doc) contains information about the SBIR and
STTR programs, regulations governing the pro-
grams, and instructional information for submission.
All of the instructions within the current
SBIR/STTR Omnibus Solicitation apply.
The principal limitations in the field of pro-
teomics are technological in nature. Proteomics, and
the sub-discipline of glycomics, are rapidly developing,
technology-intensive fields. Separations, mass spec-
trometry, microarray, bioinformatics, and other tools
have advanced rapidly to support the explosive growth
of biomedical applications in this area. However, tech-
nologies and methods remain largely inadequate to
address the majority of meaningful biological prob-
lems, particularly with respect to quantitative and real
time measurements. Continued intensive development
of advanced tools is essential to meet two needs. First,
improvements in basic bioanalytical technologies are
essential to these endeavors. This includes but is not
restricted to robotics, sample preparation and pre-frac-
tionation, analytical separations, gel and array imaging,
quantitation, mass spectrometry, intelligent automated
data acquisition, and database searching. Second,
improved informatics technologies are essential for the
conversion of data into meaningful results and interac-
tion models. Improved informatics tools will also facili-
tate the integration and synergistic development of the
basic analytical tools mentioned above. Additionally,
the translation of advances in proteomics to a clinical
setting should be a priority.
Proteomics is a rapidly expanding ﬁeld. Many of
the potential scientific and medical rewards of pro-
teomics’ successful application to complex systems seem
deceptively near. A broad range of technologies is evolv-
ing rapidly to meet the needs of the ﬁeld. However,
despite explosive growth in both academic and com-
mercial efforts, concrete technical capabilities are far
from adequate to realize this promise. Proteomics tech-
nologies and methods in the three broad, interacting
domains of biology, analytical chemistry, and informat-
ics are still largely inadequate to address the bulk of
challenging biological problems. This is the case with
respect to both core capabilities and scale.
The broad scope of proteomics might perhaps be
broken down into six types of questions that are
addressed in some form: (1) identiﬁcation of individ-
ual proteins, (2) recognition of protein interactions,
(3) relative quantitation to distinguish differential
expression of proteins, (4) characterization of post-
translational modiﬁcations, (5) qualitative or quanti-
tative measurements at high spatial and/or temporal
resolution to address the dynamics of protein interac-
tions, and (6) formulation of models based on results
from components 1-5.
The categories above deﬁne the type of informa-
tion being sought, and imply the need for technolo-
gies capable of addressing the challenges inherent in
each type of experiment. Those speciﬁc technologies
may reside within any of the three domains that
define proteomics, or may function as a bridge
between them. For example, tools for tissue or subcel-
lular fractionation may reside squarely in the biologi-
cal domain, but could also be designed in such a way
as to maximize synergy with widely used analytical
separations methods.
It is important that in a field as complex and
interdisciplinary as proteomics, technology develop-
ment be pursued with a sound understanding of con-
text. One area of particular interest is the development
of technologies that will permit observations to be
quantitative and made in real time, whether for clinical
studies or experimental systems.
In addition to the development of broadly
applicable research tools that address the core techni-
cal challenges in proteomics, unique constraints in
two subordinate areas merit special attention. We
especially encourage applications in response to this
announcement that address the unique needs of gly-
comics and clinical proteomics, described below.
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cal setting lags far behind their use in basic science
and drug discovery. Though this is not due solely to
technological constraints, the unique challenges asso-
ciated with development of simple, rapid, and robust
technologies for the clinic demand a somewhat differ-
ent perspective than might be taken in consideration
of a purely research-driven project. Likewise, this dif-
ference in perspective and priorities should open the
possibility of approaches that might be wholly inade-
quate from a research perspective but may be appro-
priate in the clinic. Finally, the exploitation of
insights previously developed in research-oriented
proteomics to develop more speciﬁc, robust tools for
clinical applications is also an appropriate goal.
The complexity and diversity of glycosylation
signiﬁcantly complicates the linkage between genetic
sequence and mature, active proteins. Glycobiology-
focused proteomics, or glycomics, requires the devel-
opment of novel approaches and tools directed at the
special challenges of glycobiology. Among post-trans-
lational modiﬁcations, glycosylation is the only one
that requires structural characterization of the modi-
fying moiety beyond noting its presence. Strategies
for separation, profiling, quantitation, and detailed
characterization of carbohydrate structures are central
challenges. Informatics tools are needed for data han-
dling and reduction, correlation of carbohydrate and
protein information, and a variety of other purposes.
Discovery-based analytical tools that can survey the
complexities of glycosylation on a system-wide basis
may have signiﬁcant biological impact. 
The goals of this PA are deliberately discussed
with respect to fundamental challenges, rather than
in relation to specific technologies, in order to
emphasize the overriding importance of surmounting
obstacles, irrespective of the analytical strategy
adopted to pursue those solutions. This solicitation is
open to unconventional or alternative approaches.
This PA uses the SBIR and STTR mechanisms,
which are set-aside programs. As an applicant, you
will be solely responsible for planning, directing, and
executing the proposed project. Future unsolicited,
competing- continuation applications based on this
project will compete with all SBIR/STTR applica-
tions and will be reviewed according to the customary
peer review procedures.
This PA uses just-in-time concepts. It also uses the
modular budgeting format. Speciﬁcally, if you are sub-
mitting an application budget of $100,000 total costs
(direct, F&A and fee) or less, use the modular format
and instructions as described in the current
SBIR/STTR Omnibus Solicitation. Otherwise follow
the instructions for non-modular budget research grant
applications. This program does not require cost shar-
ing as defined in the current NIH Grants Policy
Statement at http://grants.nih.gov/grants/policy/
nihgps_2003/NIHGPS_Part2.htm#matching_or_cost
_sharing.
Applications may be submitted for support as
Phase I STTR (R41) or Phase I SBIR (R43) grants;
Phase II STTR (R42) or Phase II SBIR (R44) grants;
or the SBIR/STTR FAST-TRACK option as
described in the SBIR/STTR Omnibus Solicitation.
Phase II applications in response to this PA will only
be accepted as competing continuations of previously
funded NIH Phase I SBIR/STTR awards. The Phase
II application must be a logical extension of the Phase
I research but not necessarily a Phase I project sup-
ported in response to this PA. 
The PHS 398 research grant application must be
used for all SBIR/STTR Phase I, Phase II and Fast-
Track applications (new and revised.) Effective October
1, 2003, applications must have a DUN and Bradstreet
(D&B) Data Universal Numbering System (DUNS)
number as the Universal Identiﬁer when applying for
federal grants or cooperative agreements. The DUNS
number can be obtained by calling 866-705-5711 or
through the website at http://www.dunandbradstreet.
com/. The DUNS number should be entered on line
11 of the face page of the PHS 398 form. The PHS
398 is available at http://grants.nih.gov/grants/fund-
ing/phs398/phs398.html. Prepare your application in
accordance with the SBIR/STTR Omnibus
Solicitation and the PHS 398. Helpful information
for advice and preparation of the application can be
obtained at: http://grants.nih.gov/grants/funding/sbir-
grantsmanship.pdf. The NIH will return applications
that are not submitted on the 5/2001 version of the
PHS 398. For further assistance contact GrantsInfo,
301-435-0714, e-mail: GrantsInfo@nih.gov. The title
and number of this PA must be typed on line 2 of the
face page of the application.
The CSR will not accept any application in
response to this PA that is essentially the same as one
currently pending initial review unless the applicant
withdraws the pending application. The CSR will not
accept any application that is essentially the same as
one already reviewed. This does not preclude the sub-
mission of a substantial revision of an unfunded ver-
sion of an application already reviewed, but such
application must include an Introduction addressing
the previous critique.
Receipt and review schedule: see http://grants.
nih.gov/grants/funding/sbirsttr_receipt_dates.htm. 
Contact: Douglas M. Sheeley, Division of
Biomedical Technology, National Center for Research
Resources, 6701 Democracy Blvd, MSC 4874,
Bethesda, MD 20892-4874 USA, 301-435-0755, fax:
301-480-3659, e-mail: sheeleyd@mail.nih.gov; Pamela
A. Marino, NIGMS, Rm 2As.43k, Natcher Building,
Bethesda, MD 20892-6200 USA, 301-594-3827, fax:
301-480-2802, e-mail: marinop@nigms.nih.gov;
Susan E. Old, Division of Heart and Vascular Disease,
NHLBI, 6701 Rockledge Dr, MSC 7940, Bethesda,
MD 20892-7940 USA, 301-435-1802, fax: 301 480-
1335, e-mail: olds@nhlbi.nih.gov; Danilo A. Tagle,
Neuroscience Center, NINDS, Rm 2133, 6001
Executive Blvd, Bethesda, MD 20892-0001 USA,
301-496-5745, fax: 301-402-1501, e-mail:
tagled@ninds.nih.gov.
Reference: PA No. PA-04-089
Intellectual Property Rights in Genetics and
Genomics
The purpose of this RFA is to encourage the study of
the role of laws and policies regarding intellectual prop-
erty rights in genetics and genomics research and devel-
opment, and the effect of such laws and policies on
progress in these ﬁelds and on commercialization, drug
development, health care delivery, and the public health.
Since its inception, the Human Genome Project
has attempted to follow a policy of free and open
access to genetic and genomic data e.g., National
Human Genome Research Institute (NHGRI) Policy
Regarding Intellectual Property of Human Genomic
Sequence (April 9, 1996), http://www.genome.gov/
10000926; NHGRI Policy on Human Genomic
Sequence Data (Dec. 21, 2000), http://www.
genome.gov/10000910. The National Institutes of
Health (NIH) policy recognizes the appropriateness
of intellectual property protections for discoveries
that are associated with useful products, but promotes
the free dissemination of research tools whenever pos-
sible, especially when the prospect of commercial gain
is remote (Report of the National Institutes of Health
(NIH) Working Group on Research Tools, http://
www.nih.gov/news/researchtools/).
Over the past three decades, however, many
patents have been granted on gene sequences and
other types of basic information derived from genetic
sequence. For some, this has generated apprehension
that gene patents are being granted too broadly or
freely, especially for foundational tools. The concern
is that the too-liberal issuance of such patent rights,
especially when coupled with exclusive licensing prac-
tices, will result in the imposition of reach-through
restrictions or excessive fees, and inhibit investigators
from conducting additional research with these tools.
This, it is feared, will ultimately be to the detriment
of advances in medical research and to public health.
In January 2001, partly in response to a letter
from the NIH urging the implementation of stricter
criteria for the issuance of biotechnology patents, the
U.S. Patent and Trademark Ofﬁce revised its guide-
lines to patent examiners regarding patents on DNA
sequence and sequence-derived intellectual property,
effectively “raising the bar” on utility standards in this
area [U.S. Patent and Trademark Office, Utility
Examination Guidelines, Fed Reg 66(4) (January 5,
2001)]. However, questions remain about whether this
revision raised the “bar” high enough to serve the pub-
lic interest. An example of the potential problem is the
recent acquisition and aggressive pursuit by Genetic
Technologies Limited (GTG), an Australian company,
of exceptionally broad global patent protection cover-
ing the use of information to derive risks of disease in
all non-coding regions of the genome [see Nature
(2003) 423:105]. While this is perhaps an extreme
example (and the validity of GTG’s patents has not yet
been tested in the courts), other controversial cases can
also be cited (e.g., the Myriad Genetics BRCA1 patent,
the University of Miami Canavan disease patent, the
CCR5 HIV co-receptor gene patent). Such cases are
increasingly leading genetics and genomics researchers,
business entities, health care providers, and consumers
to question how the balance between providing intel-
lectual property protection and fostering biomedical
innovation can best be attained.
Issues regarding the appropriate scope of protec-
tion for intellectual property rights in genetics and
genomics research and development will only increase
in complexity as progress in these ﬁelds continues. For
example, large-scale proteomics efforts [such as protein
biomarker discovery projects, the NIGMS Protein
Structure Initiative (http://www.nigms.nih.gov/psi/)
and initiatives to characterize protein-protein interac-
tions] will generate new types of potentially patentable
information, and with this information, new intellec-
tual property challenges. Such challenges will also arise
in several areas of research being emphasized under the
new NIH Roadmap Initiative (http://nihroadmap.
nih.gov/). For example, in the “chemical genomics”
area, questions will arise about whether patents should
be ﬁled on the compounds that will be discovered or
whether to place such compounds in the public
domain, and about how pricing should be determined
should a compound discovered through this process
end up as a drug. In the bioinformatics and computa-
tional biology area, questions will arise about how best
to promote the widespread distribution of new soft-
ware to be developed (e.g., using an open source model
of licensing or some other model).
Anticipating the growing need to confront ques-
tions of this type, the NHGRI has identiﬁed address-
ing intellectual property issues as one of the “Grand
Challenges” for the future of genomics. Speciﬁcally,
the Institute’s document “A Vision for the Future of
Genomics Research,” [Nature (2003) 422:835-847],
also available at: http://www.genome.gov/11006873),
called for “the development of policy options in the
area of intellectual property that will facilitate the
widespread use of genetic and genomic information
in both research and clinical settings.” To be maxi-
mally informed and effective, however, the develop-
ment of such policy options must be based on a solid
and broad-based body of theoretic and empiric data.
While a number of studies already conducted or now
underway provide a good preliminary foundation on
which to build, there is a clear need for additional
research and scholarship in this area.
In 2004, the Board on Science Technology and
Economic Policy (STEP Board) and the Science,
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Academies of Sciences convened a committee on
Intellectual Property in Genomic and Protein
Research and Innovation (the “NAS Committee”).
The NAS Committee’s charge is to review the patent-
ing and licensing of human genetic material and pro-
teins and their implications for biomedical research,
therapeutic and diagnostic products, and medical
practice. The NAS Committee is expected to release
its report in the Summer of 2005, but there will
clearly be a need for other, more in depth, examina-
tions and analyses of these issues, by investigators
from a broad range of disciplines.
To assist in addressing this need, the NHGRI
proposes a new initiative to encourage the study of
the role of laws and policies regarding intellectual
property rights in genetics and genomics research and
development, and the effect of such laws and policies
on progress in these ﬁelds and on commercialization,
drug development, health care delivery, and public
health. The initiative is designed to support rigorous,
carefully focused legal, statistical, economic, political
science, historical, and other social scientiﬁc investi-
gations, both theoretical and empirical.
As used in this RFA, the term “genetics and
genomics” includes genomics (broadly defined to
include both nucleic acid and protein products of
large-scale analyses of the human and other genomes
and methods for identifying and analyzing them) and
human molecular genetics. The term is not, however,
meant to include all of biotechnology, although the
line between genomics and biotechnology is fre-
quently hard to deﬁne. For example, the term “genet-
ics and genomics subject matter” includes the
following: (1) Both individual elements of data and
comprehensive databases or other resources regarding
genes and gene fragments; gene regulatory sequences;
ESTs; SNPs; haplotypes; proteins and protein struc-
tures; protein-protein interactions; cellular pathways;
computational models of the cell; gene expression pro-
ﬁling (microarrays); small molecules; and mouse (or
other animal) knockouts. (2) The relationships
between diseases or traits and genes, SNPs, haplo-
types, or proteins; the relationships among genotype,
environment, and phenotype (e.g., in large databases);
and the use of such information in diagnostics. (3)
Fundamental tools or methods for the production or
analysis of data or databases of the types listed above,
the bioinformatics software to probe the databases,
and the algorithms that the software elaborates. The
term “genetics and genomics subject matter” as used
in this initiative does not, however, include such sub-
ject matter as biomedical devices, engineered tissues,
stem cells, large-scale cell culture, whole organism
cloning, or individual treatment applications.
Some examples of appropriate topic areas, with
examples of speciﬁc research questions for each area, are
listed below. Investigators are welcome to propose
research in one or more of these topic areas, or in simi-
lar areas. Investigators should not be constrained by the
speciﬁc research questions included on this list. The
focus of the research, however, should remain on intel-
lectual property rights to genetics and genomics-related
subject matter, and should not be so broad as to
encompass other major areas of biotechnology. (1)
Types of Intellectual Property Rights and Related
Policy Implications. What types of intellectual property
rights to genetics and genomics-related subject matter
are being, or should be, sought, obtained, or refused?
What types of entities are seeking, obtaining, or being
refused, intellectual property rights in this ﬁeld? What
are, or should be, the standards for novelty, non-obvi-
ousness, and utility in this ﬁeld? What is, or should be,
the breadth of the claims in this ﬁeld? Do intellectual
property rights to genetics and genomics-related subject
matter beneﬁt the public when there is no identiﬁable
product? What has been the effect of intellectual prop-
erty rights in this ﬁeld on research in the private sector?
What are the mechanisms, existing or proposed as well
as legal or business custom, for protecting information
contained in databases generally, and what are the pol-
icy implications of allowing or refusing protection for
genomic and genetic databases, whether through intel-
lectual property or sui generis protection? What is, or
should be, the role of patents, copyrights, trade secrets,
and sui generis intellectual property rights for various
data types? How do the laws governing patents, copy-
rights, trade secrets, and sui generis intellectual property
rights act as an incentive, a disincentive, or a neutral
factor in determining the planning, content, and
progress of genetics and genomics research and develop-
ment programs? (2) Ownership and Assignment of
Intellectual Property Rights and Related Policy
Implications. What are, or should be, the mechanisms
for exploiting intellectual property rights to genetics and
genomics-related subject matter? How frequently are,
or should, such rights be assigned (e.g., sold, or licensed
exclusively or non-exclusively to third parties)? What
are, or should be, the usual mechanisms of such assign-
ments? Who are, or should be, the usual parties to such
assignments? To what extent would genetics and
genomics subject matter be treated differently if the cor-
responding intellectual property rights were not
assigned? What are, or should be, the practices of
biotechnology and pharmaceutical companies regard-
ing the sharing of commercially valuable data? What
are, or should be, the practices of universities regarding
the sharing of commercially valuable data (government
funded and non-government funded)? How have uni-
versities interpreted the Bayh-Dole Act, and what has
been the impact of Bayh-Dole on genetics and
genomics research? Are, or should, assignments in this
field under Bayh-Dole typically be pursuant to
employment contract or policies, or the result of arms-
length negotiations? What is the practical impact of
restrictions or limitations on the ownership of intellec-
tual property rights imposed by government funding
agencies (such as “Declaration of Exceptional
Circumstances”)? How will the mechanisms of assign-
ment of intellectual property rights, and restrictions on
such assignment, likely affect genetics and genomics
subject matter in the future? (3) Licensing Practices and
Related Policy Implications. What are the categories of
genetics and genomics subject matter for which intellec-
tual property rights are licensed or may be licensed in
the future? What are the relative numbers of intellectual
property rights involving genetics and genomics subject
matter that are subject to licensing arrangements? What
are the terms of such licenses (including exclusivity ver-
sus non-exclusivity, royalty rates, ﬁelds of use restric-
tions, etc.), and who are the parties to such agreements?
What are the structures for such licensing arrangements
(e.g., cross-licensing, block or blanket licenses, compul-
sory licenses, etc.)? What are the structures and opera-
tion of patent pools? How are end user license
agreements (EULAs) attached to the sale of research
tools being used, and how broad are their “reach-
through” provisions? To what extent might the genetics
and genomics subject matter be differently treated if the
corresponding intellectual property rights were not
licensed or were not disclosed and treated as a trade
secret? How are the planning, content, and progress of
genetics and genomics research and development pro-
grams affected by refusals to license or offers to license
on unacceptable terms? How does the way in which
genetics and genomics subject matter is licensed affect
the prospects for commercialization? What is the effect
of being required to obtain multiple licenses to conduct
some types of research or clinical tests? Does an open
source model of licensing genomic software tools
increase the usefulness of the tools and improve their
acceptance in the research community? Are intellectual
property rights involving genetics and genomics subject
matter to which licensing arrangements pertain more or
less likely to be involved in infringement litigation?
What would be the policy implications of limiting
exclusive licenses in the ﬁeld of genetics and genomics
to therapeutics and vaccines (i.e., excluding diagnos-
tics)? (4) Enforcement and Related Policy Implications.
What are the categories of genetics and genomics sub-
ject matter for which the intellectual property rights
have been involved in administrative or judicial action?
What legal issues have been raised in such lawsuits, and
who have been the parties to such lawsuits? What has
been the resolution of such cases (e.g., dismissal, settle-
ment, administrative action, trial verdict or judgment,
appellate judgment, remedies and relief awarded, etc.)?
What are the relative numbers of intellectual property
rights involving genetics and genomics subject matter
that have been ﬁled in various forums? What are the
numbers of intellectual property rights involving genet-
ics and genomics subject matter that have been chal-
lenged but that do not actually reach litigation? How
frequently are cease and desist letters issued, and how
do universities or companies respond to them? How
have the planning, content, and progress of genetics
and genomics research and development programs been
affected by threat, actual or perceived, of infringement
litigation? What strategies are employed to allocate the
risk of, to prepare for, or to defend against, infringe-
ment litigation? What impact has Madey v. Duke, 64
USPQ2d 1737, 307 F.3d 1351 (Fed Cir 2002), cert.
Denied, 156 L.3d. 656 (2003), interpreting the experi-
mental use (research) exemption to patent infringement
in the context, had in the context of academic research?
What would be the policy implications of formalizing a
research exemption in the patent law? (5) International
Issues and Related Policy Implications. What are the
categories of genetics and genomics subject matter for
which intellectual property rights have been or may be
sought both in the United States and abroad? How
does the operation of intellectual property rights involv-
ing genetics and genomics subject matter differ in the
United States from other countries (e.g., what are the
differences in the criteria for patentability applied in the
U.S. and by other major patent offices, such as in
Europe and Japan)? What mechanisms of procurement,
ownership, licensing, and enforcement (or restrictions
on these activities) exist only in other countries, and
what are the advantages and disadvantages of such?
How are international treaty obligations likely to affect
the laws and customs in the United States governing
intellectual property rights to genetics and genomics
related subject matter? How do territorial and jurisdic-
tional limitations on intellectual property rights affect
the planning, content, and progress of genetics and
genomics research and development programs? (6)
Overarching Issues. Has the planning, content, and
progress of genetics and genomics research and develop-
ment programs been enhanced, or conversely chilled,
by intellectual property rights? Have intellectual prop-
erty rights positively or negatively affected the quantity
and quality of the publication of scientiﬁc advances
involving genetics and genomics, or the timing of data
release and publication? What are the legal and practical
implications for unfettered research activities (e.g., the
signiﬁcance of a bona ﬁde research use exemption to
patent infringement, a fair use defense to copyright
infringement, a reverse engineering exception to trade
secret misappropriation, etc.)? Are existing mechanisms
of protection of intellectual property rights to genetics
and genomics related subject matter adequate or inade-
quate to the task of striking the proper balance between
intellectual property rights and open access to devices,
methods, products and data involved in genetics and
genomics research and development? How have intel-
lectual property rights to genetics and genomics-related
subject matter positively or negatively affected public
access to health care (e.g., accelerated or delayed the
commercial availability of diagnostics or treatments,
increased or decreased their cost, etc.)?
A major goal of this initiative is to help expand the
research base necessary to inform the future develop-
ment of policy options regarding intellectual property
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development. In this sense, the proposed development
of policy options by applicants to this initiative is not
required, but is encouraged when feasible. Investigators
may propose to examine existing databases related to
biotechnology and intellectual property rights or to
gather new empirical data. However, proposals that are
primarily dependent on data mining efforts should
identify and incorporate innovative analytical method-
ologies to interpret the data.
Although applications for proposals to examine
issues regarding intellectual property, genetics, and
genomics in the speciﬁc context of differing cultures
and belief systems are beyond the scope of this initia-
tive, the NHGRI encourages research on these topics
as part of its regular research program in the area of
Ethical, Legal, and Social Implications (ELSI).
Applicants interested in conducting research on such
topics are strongly encouraged to consider submitting
R01 or R03 applications under one of the appropri-
ate standing NHGRI PAs for the ELSI Program. See
http://grants.nih.gov/grants/guide/pa-files/PA-04-
050.html (R01 Program Announcement); http://
grants.nih.gov/grants/guide/pa-ﬁles/PA-04-051.html
(R03 Program Announcement).
This RFA will use NIH R01 and R03 award
mechanisms. Applicants are solely responsible for
planning, directing, and executing the proposed pro-
ject. This RFA is a one-time solicitation. Future
unsolicited, competing-continuation applications
based on this project will compete with all investiga-
tor-initiated applications and will be reviewed accord-
ing to the customary peer review procedures. The
earliest anticipated award date is 15 July 2005.
Applications that are not funded in the competition
described in this RFA may be resubmitted as new
investigator-initiated applications using the standard
receipt dates for new applications described in the
instructions to the PHS 398 application.
This RFA uses just-in-time concepts. It also uses
the modular as well as the non-modular budgeting
formats (see http://grants.nih.gov/grants/funding/
modular/modular.htm ).
Annual meetings of investigators will be held.
This will facilitate the sharing of information,
encourage collaboration, reduce possible duplication
of effort, and promote more rapid dissemination of
research ﬁndings. The initial meeting will take place
shortly after the awards are made. Funds for travel to
these meetings for up to two investigators per year
should be included in the requested budget.
Prospective applicants are asked to submit a let-
ter of intent that includes the following information:
descriptive title of the proposed research; name,
address, and telephone number of the Principal
Investigator; names of other key personnel; partici-
pating institutions; number and title of this RFA.
Although a letter of intent is not required, is not
binding, and does not enter into the review of a sub-
sequent application, the information that it contains
allows Institute Center (IC) staff to estimate the
potential review workload and plan the review.
Applications must be prepared using the PHS 398
research grant application instructions and forms (rev.
5/2001). Applications must have a DUN and Bradstreet
(D&B) Data Universal Numbering System (DUNS)
number as the Universal Identiﬁer when applying for
federal grants or cooperative agreements. The DUNS
number can be obtained by calling 866-705-5711 or
through the website at http://www.dunandbradstreet.
com/. The DUNS number should be entered on line
11 of the face page of the PHS 398 form. The PHS
398 document is available at http://grants.nih.gov/
grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo, 301-
435-0714, e-mail: GrantsInfo@nih.gov.
The RFA label available in the PHS 398 (rev.
5/2001) application form must be affixed to the
bottom of the face page of the application. Type the
RFA number on the label. Failure to use this label
could result in delayed processing of the application
such that it may not reach the review committee in
time for review. In addition, the RFA title and num-
ber must be typed on line 2 of the face page of the
application form and the YES box must be marked.
The RFA label is also available at: http://grants.nih.
gov/grants/funding/phs398/label-bk.pdf.
The Center for Scientiﬁc Review (CSR) will not
accept any application in response to this RFA that is
essentially the same as one currently pending initial
review, unless the applicant withdraws the pending
application. However, when a previously unfunded
application, originally submitted as an investigator-
initiated application, is to be submitted in response to
an RFA, it is to be prepared as a new application.
That is, the application for the RFA must not include
an introduction describing the changes and improve-
ments made, and the text must not be marked to
indicate the changes from the previous unfunded ver-
sion of the application.
Letters of intent are due 21 October 2004, with
applications due 18 November 2004. The earliest
anticipated start date is 15 July 2005.
Contact: Jean E. McEwen, NHGRI, Division of
Extramural Research, Ethical, Legal, and Social
Implications Program, 5635 Fishers Lane, Suite
4076, MSC 9305, Bethesda, MD 20892-9305 USA,
until 28 June 2004: 301-402-4997, after 28 June
2004: 301-496-7531, fax: 301-402-1950, e-mail:
jm522n@nih.gov; Rudy O. Pozzatti, NHGRI,
Scientific Review Branch, 5635 Fishers Lane, Suite
4076, MSC 9306, Bethesda, MD 20892-9306 USA,
301-402-0838, fax: 301-435-1580, e-mail:
rp7s@nih.gov.
Reference: RFA No. RFA-HG-04-004
SBIR/STTR: Circulating Cells and DNA in
Cancer Detection
Notice: This Request for Application (RFA) must be
read in conjunction with the current Omnibus
Solicitation of the National Institutes of Health (NIH),
Centers for Disease Control and Prevention (CDC),
and Food and Drug Administration (FDA) for Small
Business Innovation Research (SBIR) Small Business
Technology Trandfer (STTR) Grant Applications. The
solicitation (see http://grants.nih.gov/grants/funding/
sbirsttr1/index.pdf or http://grants.nih.gov/grants/fund-
ing/sbirsttr1/index.doc) contains information about the
SBIR and STTR programs, regulations governing the
programs, and instructional information for submis-
sion. All of the instructions within the SBIR/STTR
Omnibus Solicitation apply with the exception of the
following: special receipt dates, and initial review con-
vened by the National Cancer Institute (NCI) Division
of Extramural Activities.
The Division of Cancer Prevention of the NCI
invites small business applications for research pro-
jects to develop novel technologies for capturing,
enriching, and preserving exfoliated abnormal cells
and circulating DNA from body ﬂuids or effusions
and to develop methods to concentrate these cells and
DNA for cancer biomarker detection.
In body ﬂuids, such as sputum, the number of
exfoliated tumor cells is often low compared to the
number of normal cells, making it difﬁcult to detect
these abnormal cells by routine cytopathology.
Separation of dysplastic cells from degenerating cells
and cells undergoing non-speciﬁc reactive changes is
problematic. Moreover, exfoliated cells are frequently
contaminated with normal cells, bacteria, and cellular
debris. Therefore, enrichment methods are needed to
allow for routine detection and molecular analysis of
small numbers of exfoliated cells.
Circulating extracellular DNA was ﬁrst reported
in 1948. It has been shown that the circulating DNA
in the blood of cancer patients has genetic character-
istics identical to those of the primary tumors. Thus,
circulating DNA is an important material that may
be useful for cancer detection. Currently available
methods for isolating undegraded circulating DNA
are limited, and there is a need to develop novel
methods which improve the yield of undegraded
DNA and to adapt detection assays so that this DNA
can be used to detect mutations, microsatellite insta-
bilities, loss of heterozygosity, epigenetic changes, and
other molecular genetic changes. 
This RFA will utilize the SBIR and STTR mech-
anisms, but will be run in parallel with a program
announcement of identical scientiﬁc scope (PA-04-
035) that will utilize the exploratory/developmental
(R21) grant mechanism.
Cellular and molecular changes that ensue dur-
ing tumor progression occur over a number of years
and in an apparently stochastic manner. For example,
it takes an average of 15 to 20 years for a small ade-
nomatous polyp to become malignant. Prior to the
appearance of a morphologically identiﬁed precancer-
ous lesion, numerous genetic and molecular alter-
ations have occurred. During the early stages of
cancer development, there is a window of opportu-
nity to detect precancerous cells with genetic or mole-
cular biomarkers that identify and characterize their
progression towards cancer. Finding molecular and
genetic biomarkers of malignancy is an extraordinary
opportunity for the NCI and is particularly impor-
tant in detecting the emergence of precancerous cell
populations. In these earliest stages of neoplasia,
lesions are more likely to be amenable to eradication.
This principle has been well-demonstrated in cervical
neoplasia, where screening for dysplastic exfoliated
cells can result in a 70 percent or greater reduction in
mortality due to cervical cancer. Detection of genetic
abnormalities in preneoplastic lesions poses chal-
lenges because of the small size of lesions, the hetero-
geneity of precancerous cells, and the relatively low
number of abnormal cells compared to normal cells.
More than 80 percent of human tumors (e.g.
colon, lung, prostate, oral cavity, esophagus, stomach,
uterine cervix, and bladder) originate from epithelial
cells, often at a mucosal surface, and are clonal in ori-
gin.Cells from these tumors exfoliate spontaneously
into blood, sputum, urine, and various effusions.
Abnormalities within these exfoliated cells could be
used to detect and identify precancerous lesions or
very early stage cancers if highly sensitive technologies
were available to identify the presence of a few abnor-
mal cells among millions of normal cells. For exam-
ple, PCR has been used to detect mutant DNAs in
neoplastic exfoliated cells; mutations have been
detected in ras genes present in stool samples
obtained from patients with colorectal cancer, and in
p53 from the urine of patients with bladder cancer
and in the sputa of patients with lung cancer. Assays
to detect genetic mutations, microsatellite instability,
or hypermethylation may be adapted for use with
exfoliated cells. As these assays are complex and tech-
nically challenging, their general use will require the
development of novel technologies for isolating and
enriching abnormal exfoliated cells.
Studies performed in the early 1970s showed that
increased quantities of DNA are found in the plasma
of patients suffering from different malignancies, but it
was not until the 1990s that this circulating DNA was
shown to exhibit tumor-related alterations. Mutant
DNA has been found in the plasma of patients with
colorectal, pancreatic, biliary tree, skin, head-and-neck,
lung, breast, kidney, ovarian, nasopharyngeal, liver,
bladder, gastric, prostate, and cervical cancers as well as
in haematologic malignancies. Allelic imbalance (AI),
which involves the loss or gain of chromosomal
regions, is found in many cancers. AI can be detected
in genomic tumor DNA released into the blood after
cellular necrosis or apoptosis. These observations
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source for noninvasive diagnostic, prognostic, and fol-
low-up tests for cancer.
Precancerous exfoliated cells can be identiﬁed by
cytologic examination of washings or brushings from
bronchi, oral cavity, esophagus, stomach, bile and
pancreatic ducts, as well as of sputum and urine speci-
mens. However, the detection of these exfoliated can-
cer cells by routine cytopathological examination is
very difﬁcult because the number of abnormal cells in
the specimens is usually very low compared to the
number of normal cells. It is also difﬁcult to distin-
guish low grade dysplasia from non-speciﬁc reactive or
inﬂammatory changes due to the low sensitivity and
speciﬁcity of current diagnostic methodologies. This is
particularly true of urine cytology, where most low-
grade papillary lesions are missed by cytologic exami-
nation. Even with new PCR-based technologies with
enhanced sensitivity, current technologies for isolating
exfoliated cells are too inefficient to be of practical
utility.  Therefore, the development of novel, high-
throughput, sensitive technologies for sample prepara-
tions is a prerequisite for the successful detection of
the small number of exfoliated cells or of the small
amounts of DNA, RNA and proteins in these cells.
There are a variety of approaches to detect and
analyze precancerous and cancerous cells in body ﬂu-
ids [e.g., cytopathological analysis, morphometric
analysis, molecular biomarkers for speciﬁc receptors or
genetic changes, Fluorescence in Situ Hybridization
(FISH) analysis, or PCR-based analysis].The selection
of approach, in many instances, depends on the type
of biological specimens (sputum, bronchial washing,
cervical brushing, voided urine, etc.). Given that the
concentration of the atypical epithelial cells can be
very low compared to that of normal cells, all of these
approaches require between 1 to 10,000 and 1 million
enrichments of the atypical cells. Currently, there are
two broad categories of enrichment methods:
mechanical (centrifugation, cytospin, sucrose gradi-
ents, etc.) and antibody-based selection with mechani-
cal separation (FACS – flow-assisted cell sorting,
MACS - magnetic assisted cell sorting, etc.). While
these two types of enrichment processes can be used in
series to improve the yield, none of the currently avail-
able methods achieve sufﬁcient enrichment of atypical
cells to allow them to be routinely used for cancer
detection.
The single largest barrier to using circulating
DNA for cancer detection is the amount of circulating
undegraded DNA that can be isolated is low, making
it unsuitable for currently available assay technologies.
Several factors affect the yield and purity of circulating
DNA. Intracellular nuclease activity in both apoptotic
and necrotic cells in a particular organ affect the
degree of DNA degradation found in body fluids.
Also, the degree to which a particular tissue is repre-
sented in the total circulating DNA is dependent on
the mechanism and efﬁciency by which apoptotic cells
are eliminated from the tissue.
As with any other diagnostic technique, practical
application of circulating DNA technology is depen-
dent on concurrent increase in the sensitivity and
reproducibility of molecular based-assays. The poten-
tial use of circulating DNA for cancer detection could
be greatly enhanced by developing isolation methods
that result in less degradation and by adapting assay
methods to use the low amounts that can be isolated.
Because of the limitations of “conventional” markers,
there has been a search for additional sources of speci-
ﬁcity so as to expand the target pool of cancer-associ-
ated molecules. Circulating cells and DNA offer such
opportunity for detection molecular aberrations in
plasma/serum, or other body fluids, that accurately
reﬂect the situation in primary tumor. This will, how-
ever, require the development of methodological con-
sistencies so as to allow valid comparisons between
various assays based on circulating cells or DNA.
The primary purpose of this initiative is to
encourage the development of technologies for isolat-
ing and characterizing exfoliated cells, circulating cells,
and plasma/serum DNA. A secondary purpose is the
analytical validation of existing and/or newly devel-
oped technologies for their usefulness in cancer detec-
tion. Analytical validation refers to the measurement of
sensitivity and reproducibility of the proposed
assay/technology. The long-term goal of the technol-
ogy development is to identify a panel of well-charac-
terized biomarkers derived from exfoliated cells and/or
circulating DNA that can be sampled in a clinical set-
ting. These methodologies will be tested and validated
in future population-based clinical trials, and inte-
grated into a comprehensive information system that
will be developed under the Early Detection Research
Network (www.cancer.gov/edrn). In pursuit of these
goals, the NCI invites applications which address the
following areas: 1) Development of high-throughput,
high-yield technologies for isolating exfoliated cells, cir-
culating cells and DNA in body fluids; 2)
Development of methods for enrichment and preser-
vation of exfoliated cells, circulating cells and DNA
isolated from body ﬂuids; 3) Development of sensitive,
high-throughput molecular, cytomorphometric,
immunologic, and other relevant technologies to iso-
late and characterize tumor cells in malignant effusions
for detection of low tumor burden, to help distinguish
reactive cells from tumor cells, and to perform accurate
assays on circulating DNA; 4) Validation of the sensi-
tivity and reproducibility of current technologies for
isolating and characterizing exfoliated cells, circulating
cells and DNA isolated from body ﬂuids.
This RFA uses the SBIR and STTR mecha-
nisms, which are set-aside programs. As an applicant,
you will be solely responsible for planning, directing,
and executing the proposed project. Future unso-
licited, competing-continuation applications based
on this project will compete with all SBIR/STTR
applications and will be reviewed according to the
customary peer review procedures. The anticipated
award date is approximately 9-11 months from the
respective receipt date. Applications that are not
funded in the competition described in this RFA may
be resubmitted as new SBIR/STTR applications
using the standard receipt dates for new applications
described in the current SBIR/STTR Omnibus
Solicitation. As there are multiple receipt dates, it is
possible that an unfunded application can be resub-
mitted under this RFA as a revised application.
This RFA uses just-in-time concepts. It also uses
the modular budgeting as well as the non-modular
budgeting formats. Speciﬁcally, if you are submitting
an application budget of $100,000 total costs (direct,
F&A and fee) or less, use the modular budget format.
For applications requesting more than $100,000, use
the non-modular budget format. Instructions for
both are described in the current SBIR/STTR
Omnibus Solicitation. This program does not require
cost sharing as defined in the current NIH Grants
Policy Statement at http://grants.nih.gov/grants/pol-
icy/nihgps_2003/NIHGPS_Part2.htm.
Except as otherwise stated in this RFA, awards
will be administered under NIH grants policy as
stated in the NIH Grants Policy Statement,
December 2003, available at http://grants.nih.gov/
grants/policy/nihgps_2003/.
Applications may be submitted for support as
Phase I STTR (R41) or Phase I SBIR (R43) grants;
Phase II STTR (R42) or Phase II SBIR (R44) grants;
or the SBIR/STTR FAST-TRACK option as
described in the SBIR/STTR Omnibus Solicitation.
Phase II applications in response to this RFA will only
be accepted as competing continuations of previously
funded NIH Phase I SBIR/STTR awards. A Phase II
application must be a logical extension of the Phase I
research but not necessarily a Phase I project supported
in response to this RFA. Fast Track applications will
beneﬁt from expedited evaluation of progress following
the Phase I feasibility study for transition to Phase II
funding for expanded developmental work.
Prospective applicants are asked to submit a letter
of intent that includes the following information:
descriptive title of the proposed research; name,
address, and telephone number of the Principal
Investigator; names of other key personnel; participat-
ing institutions, number and title of this RFA.
Although a letter of intent is not required, is not bind-
ing, and does not enter into the review of a subsequent
application, the information that it contains allows IC
staff to estimate the potential review workload and
plan the review.
The PHS 398 research grant application must be
used for all SBIR/STTR Phase I, Phase II, and Fast-
Track applications (new and revised). Effective 1
October 2003, applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System
(DUNS) number as the Universal Identifier when
applying for federal grants or cooperative agreements.
The DUNS number can be obtained by calling 866-
705-5711 or through the website at http://www.
dunandbradstreet.com/. The DUNS number should be
entered on line 11 of the face page of the PHS 398
form. The PHS 398 is available at http://grants.nih.
gov/grants/funding/phs398/phs398.html. Prepare your
application in accordance with the SBIR/STTR
Omnibus Solicitation and the PHS 398. Helpful infor-
mation for advice and preparation of the application
can be obtained at http://grants.nih.gov/grants/fund-
ing/sbirgrantsmanship.pdf. The NIH will return appli-
cations that are not submitted on the 5/2001 version of
the PHS 398. For further assistance, contact GrantsInfo
301-435-0714; e-mail: GrantsInfo@nih.gov. 
Applications hand delivered by individuals to the
NCI will no longer be accepted. This policy does not
apply to courier deliveries (i.e., FEDEX, UPS, DHL,
etc.) (see http://grants.nih.gov/grants/guide/notice-
files/NOT-CA-02-002.html). This policy is similar
to and consistent with the policy for applications
addressed to Centers for Scientific Review as pub-
lished in the NIH Guide Notice at
http://grants.nih.gov/grants/guide/notice-ﬁles/NOT-
OD-02-012.html.
The Center for Scientific Research (CSR) will
not accept any application in response to this RFA
that is essentially the same as one currently pending
initial review unless the applicant withdraws the
pending application. The CSR will not accept any
application that is essentially the same as one already
reviewed. However, when a previously unfunded
application, originally submitted as an investigator-
initiated application, is to be submitted in response to
an RFA, it is to be prepared as a new application.
That is, the application for the RFA must not include
an introduction describing the changes and improve-
ments made, and the text must not be marked to
indicate the changes from the previous unfunded ver-
sion of the application.
Letters of Intent are due 17 January 2005, 16
May 2005, and 14 September 2005. Applications are
due 14 February 2005, 13 June 2005, and 12
October 2005. The earliest anticipated start dates are
January 2006, April 2006, and July 2006.
Contact: Sudhir Srivastava, Division of Cancer
Prevention, NCI, 6130 Executive Blvd, EPN Rm
3144, Bethesda, MD 20892-0001 USA, Rockville,
MD 20852 (for express/courier service), 301-496-
3983, fax: 301-402-8990, e-mail: ss1a@nih.gov; (for
peer review issues) Referral Ofﬁcer, NCI, Division of
Extramural Activities, 6116 Executive Blvd, Rm
8041, MSC 8329, Bethesda, MD 20892-8329 USA,
Rockville, MD 20852 (for express/courier service),
301-496-3428, fax: 301-402-0275, e-mail: ncire-
fof@dea.nci.nih.gov.
Reference: RFA No. RFA-CA-06-001
Fellowships, Grants, & Awards
Environmental Health Perspectives • VOLUME 112 | NUMBER 12 | August 2004 A 695